Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by George Bondi on May 30th, 2026

Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.00.

STTK has been the topic of several research reports. TD Cowen reiterated a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. Cantor Fitzgerald initiated coverage on shares of Shattuck Labs in a report on Monday, April 27th. They issued an “overweight” rating on the stock. Weiss Ratings upgraded shares of Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 19th. Wall Street Zen downgraded shares of Shattuck Labs from a “buy” rating to a “hold” rating in a research report on Saturday, May 23rd. Finally, HC Wainwright raised their price objective on shares of Shattuck Labs from $6.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, April 20th.

View Our Latest Stock Analysis on Shattuck Labs

Insider Transactions at Shattuck Labs

In other Shattuck Labs news, insider Arundathy N. Pandite sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $6.61, for a total transaction of $198,300.00. Following the completion of the sale, the insider directly owned 166,219 shares in the company, valued at $1,098,707.59. This trade represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 8.79% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STTK. AQR Capital Management LLC grew its holdings in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after buying an additional 31,355 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Shattuck Labs in the 1st quarter valued at $81,000. Acadian Asset Management LLC grew its holdings in Shattuck Labs by 27.6% in the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock valued at $243,000 after buying an additional 55,687 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Shattuck Labs in the 2nd quarter valued at $44,000. Finally, Jane Street Group LLC raised its stake in Shattuck Labs by 2,510.8% in the 2nd quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock worth $229,000 after purchasing an additional 278,576 shares in the last quarter. 58.74% of the stock is owned by institutional investors and hedge funds.

Shattuck Labs Stock Down 0.3%

STTK opened at $5.95 on Friday. Shattuck Labs has a 12-month low of $0.71 and a 12-month high of $8.33. The stock has a market cap of $456.25 million, a price-to-earnings ratio of -9.44 and a beta of 1.18. The business has a 50 day moving average of $6.67 and a 200-day moving average of $4.76.

Shattuck Labs (NASDAQ:STTK – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. During the same period last year, the firm earned ($0.27) earnings per share. As a group, analysts expect that Shattuck Labs will post -0.51 earnings per share for the current year.

Shattuck Labs Company Profile

(Get Free Report)

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.

Analyst Recommendations for Shattuck Labs (NASDAQ:STTK)

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.